Wells Fargo’s David Maris and team call Valeant Pharmaceutical International’s (VRX) earnings and guidance “worse than feared” and contend that the struggling specialty pharmaceutical company’s “debt problem [is] coming into focus.” They explain:
Reuters
Our preliminary look at 1Q results leads us to believe that Valeant is performing....More>>>